Ulcerative Colitis

Jacob said he intends to dedicate some of the funds to further development of cancer-fighting compound, Degrasyns, which the Company recently has licensed from the University of Texas' M.

D.

Anderson Cancer Center, one of the world's preeminent research institutions in the field of cancer.

"The anti-cancer activity of Degrasyns relates to its ability to selectively degrade key proteins involved in tumor cell proliferation and survival," he noted.

"This is very significant potentially because these compounds have the potential to treat not only hematological cancers, that is, blood cancers, but also solid tumor cancers, which is a whole other extremely significant area, medically, for the treatment of cancer.

It opens the drug up for a very broad number of potential applications for treatment." In an earlier interview, Dr.

Jacob described the ways in which this private placement funding would accelerate development of Callisto's anticancer drugs, L-Annamycin and Atiprimod, which have advanced to human clinical studies.

The interview is now available free of charge to all interested investors by visiting http://www.smallcapinsights.com.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions.

Callisto's drug ca...

Read more...